Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06209567 · ClinicalTrials.gov registry record · Early Phase 1
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
A Early Phase 1 study of Brain Metastases and High Grade Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
- 7
- Study locations
NCT06209567 is a Early Phase 1 study of Brain Metastases and High Grade Glioma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06209567, a Early Phase 1 study of Brain Metastases and High Grade Glioma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 68Ga-PSMA-11 PET Scans
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2027-01-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06209567
The ClinicalTrials.gov registry entry for NCT06209567 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-PSMA-11 PET Scans is the first listed.
NCT06209567 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06209567 about?
NCT06209567 is a clinical study titled "A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors". The purpose of this study is to find out whether 68Ga-PSMA-11 PET/CT is effective in assessing tumor uptake (tumor activity seen in cancerous tissue) in participants with high-grade glioma/HGG or brain metastases.
What is the current status of trial NCT06209567?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2024-01-05. Estimated completion is 2027-01-05.
What conditions does trial NCT06209567 study?
This clinical trial studies the following conditions: Brain Metastases, High Grade Glioma, Brain Metastases, Adult.
What interventions are being tested in trial NCT06209567?
The interventions under investigation include: 68Ga-PSMA-11 PET Scans (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06209567?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06209567 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
RECRUITING · Early Phase 1
-
Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.